Recommendations on the Use of 18F-FDG PET in Oncology

• DOI: 10.2967/jnumed.107.047787
• Publication Date: 2008-02-21T01:54:10Z
• Authors: James W. Fletcher; Benjamin Djulbegovic; Heloisa P. Soares; Barry A. Siegel; Val J. Lowe; Gary H. Lyman; R. Edward Coleman; Richard Wahl; John Christopher ...; Norbert Avril; Lawrence H. Einhorn; W. Warren Suh; David Samson; Dominique Delbeke; Mark Gorman; Anthony F. Shields
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Fluorodeoxyglucose F18; Neoplasms; Positron-Emission Tomography; Practice Guidelines as Topic; Humans; Nuclear Medicine; Radiopharmaceuticals; Medical Oncology; 3. Good health

The rationale was to develop recommendations on the use of ¹⁸F-FDG PET in breast, colorectal, esophageal, head and neck, lung, pancreatic, thyroid cancer; lymphoma, melanoma, sarcoma; unknown primary tumor. Outcomes interest included for diagnosing, staging, detecting recurrence or progression cancer. <b>Methods:</b> A search performed identify all published randomized controlled trials systematic reviews literature. An additional relevant unpublished reviews. These publications comprised both retrospective prospective studies varied methodologic quality. anticipated consequences false-positive false-negative tests when evaluating clinical usefulness, impact management cancer patients, were also reviewed. <b>Results Conclusion:</b>¹⁸F-FDG should be used as an imaging tool conventional radiologic methods such CT MRI; any positive finding that could lead a clinically significant change patient confirmed by subsequent histopathologic examination because risk results. appropriate setting diagnosis pancreatic is indicated staging colon, lung lymphoma melanoma. In addition, detect lymphoma.